A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

By Schelman William   Mohammed Tabraiz   Traynor Anne   Kolesar Jill   Marnocha Rebecca   Eickhoff Jens   Keppen Michael   Alberti Dona   Wilding George   Takebe Naoko   Liu Glenn  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 295-302

Springer Publishing Company

Access to resources Recommend Favorite

Treatment with irinotecan plus cisplatin has a similar survival benefit to etoposide plus cisplatin in patients with extensive-stage small cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite